{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Pieris Pharmaceuticals, Inc."},"Symbol":{"label":"Symbol","value":"PIRS"},"Address":{"label":"Address","value":"255 STATE STREET,9TH FLOOR, BOSTON, Massachusetts, 02109, United States"},"Phone":{"label":"Phone","value":"+1 857 246-8998"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of the Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. The company with the help of technology creates differentiated drugs such as PRS-080, PRS-060, PRS-343, and PRS-332 that can help patients suffering from cancer, severe asthma, anemia, and other medical conditions with a high unmet medical need. Geographically, all the operation of the firm functions through the region of the United States."},"CompanyUrl":{"label":"Company Url","value":"https://www.pieris.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Stephen S. Yoder","title":"President, Chief Executive Officer & Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}